---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-333821"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2026-08-05T11:05:22+00:00"
generated_at: "2026-08-05T11:10:50.330216+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# EyePoint Q2 net loss $94.5M ($1.09/sh); cash $180M; LUGANO data expected August 2026

## Summary
- Net loss $94.5M vs $59.4M YoY; revenue $0.5M vs $5.3M.
- Cash and investments $180M as of June 30, 2026, down from $223M at March 31, 2026.
- LUGANO Phase 3 wet AMD topline data expected in August 2026; LUCIA data Q4 2026.
- DME Phase 3 trials COMO and CAPRI fully enrolled (over 480 patients); topline data Q4 2027.
- Appointed Tarek S. Hassan, M.D., as Chief Strategic Science Officer in July 2026.

## SEC filing metadata
- accession: 0001193125-26-333821
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2026-08-05T11:05:22+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/0001193125-26-333821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-333821
- JSON: https://secwatch.observer/filing/0001193125-26-333821.json
- Plain text: https://secwatch.observer/filing/0001193125-26-333821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.